UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) April 6, 2004
HALOZYME THERAPEUTICS, INC.
 (Exact name of registrant as specified in its charter)

           Nevada                       000-49616               88-0488686
(State or other jurisdiction of  (Commission File Number)     (IRS Employer
        incorporation)                                      Identification No.)
--------------------------------------------------------------------------------	

11588 Sorrento Valley Road, Suite 17
San Diego, California 92121
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (858) 794-8889
Not Applicable
(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
On April 6, 2004, Halozyme Therapeutics, Inc. ("Halozyme") issued a press release that Robert Engler, M.D., had been named to its Board of Directors. In addition, Ira Lechner, Chairman of the Board, resigned from the Board of Directors and Jonathan Lim, M.D., Halozyme's President and Chief Executive Officer, added the post of Chairman of the Board to his duties. The foregoing is discussed in greater detail in such press release, a copy of which is filed herewith as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
The following exhibit is filed with this Form 8-K.

Exhibit No.     Description
-----------     -----------

   99.1         Press Release of April 6, 2004, regarding the
                appointment of Robert Engler, M.D., to the Board of
                Directors, the resignation of Ira Lechner from the
                Board of Directors and the appointment of Jonathan
                Lim, M.D., as Chairman of the Board.	

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HALOZYME THERAPEUTICS, INC.

Date: April 6, 2004                  By:   /s/ Jonathan E. Lim, M.D.
                                           -------------------------------------
                                           President and Chief Executive Officer	

HALOZYME THERAPEUTICS, INC.
HALOZYME CONTACT INVESTOR RELATIONS CONTACTS
David A. Ramsay Ina McGuinness or Bruce Voss Chief Financial Officer Lippert/Heilshorn & Associates
(858) 794-8889 (310) 691-7100 dramsay@halozyme.com imcguinness@lhai.com
MEDIA CONTACTS
 Kathy Sweeney/ Megan Riggs
Mentus
858-455-5500, x212/x215
kwitz@mentus.com
megan@mentus.com
HALOZYME THERAPEUTICS NAMES ROBERT ENGLER, M.D., TO BOARD OF DIRECTORS
IRA LECHNER STEPS DOWN AS CHAIRMAN OF THE BOARD;
CEO JONATHAN LIM, M.D., NAMED CHAIRMAN OF THE BOARD
SAN DIEGO, CALIF., APRIL 6, 2004 - Halozyme Therapeutics, Inc. (OTCBB: HZYM), a therapeutically driven biopharmaceutical company focused on the development and commercialization of recombinant human enzymes, today announced that Robert Engler, M.D., has been named to its Board of Directors. In addition, Ira Lechner, Chairman of the Board, is resigning from the board and Jonathan Lim, M.D., Halozyme's President and CEO, will add the post of Chairman of the Board to his duties, effective immediately.
These board changes bring the total number of board members to five, three of whom are outside members and two of whom are insiders as defined by Securities and Exchange Commission and NASDAQ rules.
"We are extremely pleased that Dr. Engler has agreed to join our board," said Dr. Lim. "He is a multi-talented leader who is credited with the founding of two successful biotech companies. His business and scientific expertise will greatly assist Halozyme as we continue to pursue the company's multiple market opportunities and execute our capital-efficient business model. At the same time, we are sorry to see Ira step down, as he has made an invaluable contribution to Halozyme's early development. We wish Ira the best as he focuses on his other business and not-for-profit interests."
Dr. Engler spent his career as a Cardiologist at the Veterans Affairs Medical Center and the University of California, San Diego, where he retired as Professor Emeritus in 2001. While at the VA Medical Center, Dr. Engler served as Associate Chief of Staff and Chief of Research and was an attending physician, in addition to running an active cardiovascular research laboratory. His research and clinical work led to the founding of two successful biotechnology companies: Gensia, Inc., and Collateral Therapeutics, Inc.

HALOZYME THERAPEUTICS NAMES ROBERT ENGLER, M.D., TO BOARD OF DIRECTORS
PAGE 2
He also founded and served as President of the Veterans Medical Research Foundation. Dr. Engler graduated from Georgetown Medical School.
Halozyme's recombinant human enzyme technology replaces current animal slaughterhouse-derived enzymes that carry risks of animal pathogen contamination and immunogenicity. The Company believes that the versatility of its first enzyme, rHuPH20, will enable Halozyme to simultaneously market the product as a medical device, a drug enhancement agent, and a therapeutic biologic.
ABOUT HALOZYME THERAPEUTICS, INC.
 Halozyme is a therapeutically driven biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product portfolio is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's lead products offer a safe and pure alternative to existing slaughterhouse-derived extracts that carry risks of animal pathogen contamination and immunogenicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to significantly impact the quality of medicine while creating long-term shareholder value.
SAFE HARBOR STATEMENT
 In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the marketing and distribution methods Halozyme intends to employ with respect to its first enzyme) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believes," "execute," "enable" and other words of similar meaning. Factors that may result in differences are discussed in greater detail in Halozyme Therapeutics' Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.
# # #